EP3666797
ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
Zusammenfassung
[0001] Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Anmelder
AMGEN INC [US]
Erfinder
JACKSON SIMON MARK [US]WALKER NIGEL PELHAM CLINTON [US]PIPER DEREK EVAN [US]SHAN BEI [US]SHEN WENYAN [US]CHAN JOYCE CHI YEE [US]KING CHADWICK TERENCE [CA]KETCHEM RANDAL ROBERT [US]MEHLIN CHRISTOPHER [US]CARABEO TERESA ARAZAS [US]CAO QUIONG [US]
Externe Quellen
Klassifikation
IPC-Klassen
A61K 31/22A61K 31/366A61K 31/40A61K 31/405A61K 31/44A61K 31/47A61K 31/505A61K 31/66A61K 39/395A61K 45/06A61P 3/06C07K 16/40
CPC-Klassen
A61K 31/22A61K 31/366A61K 31/40A61K 31/405A61K 31/44A61K 31/47A61K 31/505A61K 31/66A61K 39/395A61K 39/3955A61K 45/06A61P 25/28A61P 3/00A61P 3/06A61P 43/00A61P 7/00A61P 9/00A61P 9/10C07K 16/40C12N 15/1137
AI: Life Sciences
warum
Amgen anti-PCSK9 antibody — A61K39/395 + A61P3/06 + C07K16/40. Pure biopharma.